tiprankstipranks
Trending News
More News >
Orexo AB (ORXOF)
OTHER OTC:ORXOF
US Market
Advertisement

Orexo AB (ORXOF) Earnings Dates, Call Summary & Reports

Compare
7 Followers

Earnings Data

Report Date
Oct 23, 2025
Before Open (Confirmed)
Period Ending
2025 (Q3)
Consensus EPS Forecast
-0.05
Last Year’s EPS
-0.13
Same Quarter Last Year
Based on 0 Analysts Ratings

Earnings Call Summary

Q3 2024
Earnings Call Date:Oct 24, 2024|
% Change Since:
|
Earnings Call Sentiment|Neutral
The earnings call presented a mixed view with notable achievements in ZUBSOLV demand stabilization in the Commercial segment and promising developments in the AmorphOX platform. However, these were offset by challenges such as the decline in ZUBSOLV revenues, delays in OX124 approval, and increased legal costs, which impacted financial performance and raised liquidity concerns.
Company Guidance
During Orexo's Q3 2024 earnings call, CEO Nikolaj Sørensen and CFO Frederik Jarrsten provided detailed guidance on various financial and operational metrics. The company's total revenue for the quarter was approximately SEK 136 million, with ZUBSOLV contributing SEK 131 million, marking a 6.7% year-over-year decline due to a weaker USD FX rate and reduced demand from the public sector. However, the Commercial segment exhibited robust growth, increasing by 22% from the previous year, despite a slight decline in Medicaid. Orexo's gross margin remained high at 86%, and operating expenses were reduced by 15% compared to the previous year. The company anticipates positive EBITDA for the full year, although inventory adjustments and potential DOJ investigation settlements could impact future financial results. Sørensen highlighted the importance of the upcoming FDA meeting regarding OX124 and expressed optimism about the stabilization in ZUBSOLV demand, particularly in the Commercial segment, which is more profitable. The company is also exploring strategic options to enhance its equity position and leverage its AmorphOX platform for future growth.
ZUBSOLV Growth in Key Segment
ZUBSOLV showed stabilization in demand with growth in the Commercial segment year-over-year and quarter-over-quarter. The Commercial segment grew by 22% from the previous year, which is significant for profitability since it's more profitable than Medicaid and Medicare segments.
Successful Human Factor Study for OX124
Orexo completed a new Human Factor study for OX124, which was successful in addressing issues raised by the FDA regarding instructions for use.
AmorphOX Platform Opportunities
The AmorphOX platform has continued to show potential with ongoing feasibility projects in various chemical structures, including vaccines and biologics, indicating a stable formulation across small molecules and peptides.
Positive EBITDA Outlook
Orexo maintained a high gross margin of 86% and expects to achieve a positive EBITDA for the full year, despite current challenges.

Orexo AB (ORXOF) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

ORXOF Earnings History

Report Date
Fiscal Quarter
Forecast / EPS
Last Year's EPS
EPS YoY Change
Press Release
Slides
Play Transcript
Oct 23, 2025
2025 (Q3)
-0.05 / -
-0.126
Jul 16, 2025
2025 (Q2)
-0.04 / -0.13
-0.109-15.38% (-0.02)
May 06, 2025
2025 (Q1)
-0.13 / -0.05
-0.027-76.92% (-0.02)
Feb 06, 2025
2024 (Q4)
-0.17 / -0.35
-0.056-524.07% (-0.30)
Oct 24, 2024
2024 (Q3)
-0.08 / -0.13
-0.101-24.74% (-0.03)
Jul 17, 2024
2024 (Q2)
-0.04 / -0.11
-0.039-181.08% (-0.07)
May 08, 2024
2024 (Q1)
-0.08 / -0.03
-0.19486.02% (+0.17)
Feb 08, 2024
2023 (Q4)
-0.05 / -0.06
-0.27979.78% (+0.22)
Nov 02, 2023
2023 (Q3)
-0.10 / -0.10
-0.08-25.97% (-0.02)
Jul 18, 2023
2023 (Q2)
-0.10 / -0.04
-0.10964.42% (+0.07)
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed

ORXOF Earnings-Related Price Changes

Report Date
Price 1 Day Before
Price 1 Day After
Percentage Change
Jul 16, 2025
$2.08$1.94-6.73%
May 06, 2025
$1.08$1.080.00%
Feb 06, 2025
$1.08$1.080.00%
Oct 24, 2024
$1.22$1.08-11.48%
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Orexo AB (ORXOF) report earnings?
Orexo AB (ORXOF) is schdueled to report earning on Oct 23, 2025, Before Open (Confirmed).
    What is Orexo AB (ORXOF) earnings time?
    Orexo AB (ORXOF) earnings time is at Oct 23, 2025, Before Open (Confirmed).
      Where can I see when companies are reporting earnings?
      You can see which companies are reporting today on our designated earnings calendar.
        What companies are reporting earnings today?
        You can see a list of the companies which are reporting today on TipRanks earnings calendar.
          What is ORXOF EPS forecast?
          ORXOF EPS forecast for the fiscal quarter 2025 (Q3) is -0.05.
            What am I Missing?
            Make informed decisions based on Top Analysts' activity
            Know what industry insiders are buying
            Get actionable alerts from top Wall Street Analysts
            Find out before anyone else which stock is going to shoot up
            Get powerful stock screeners & detailed portfolio analysis